Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Daily

Download Data

Theseus Pharmaceuticals Inc Price to Book Ratio (P/B) on February 23, 2024

Theseus Pharmaceuticals Inc Price to Book Ratio (P/B) is NA on February 23, 2024, a NA change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Theseus Pharmaceuticals Inc 52-week high Price to Book Ratio (P/B) is 2.04 on May 04, 2023, which is NA below the current Price to Book Ratio (P/B).
Theseus Pharmaceuticals Inc 52-week low Price to Book Ratio (P/B) is 0.41 on November 10, 2023, which is NA below the current Price to Book Ratio (P/B).
Theseus Pharmaceuticals Inc average Price to Book Ratio (P/B) for the last 52 weeks is 1.05.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends